News | May 17, 2024
Cresset opens new new India HQ in Bengaluru to tap potential of APAC market
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Application based on results from the TROPION-Breast01 Phase III trial
This acquisition enables MTD to open new, strategic markets
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Subscribe To Our Newsletter & Stay Updated
